臨床泌尿器科63巻5号

2009年04月発行

特集 泌尿器科の癌薬物療法―ここが聞きたい

膀胱癌―今日においてもBCGおよびMVACは標準治療か？

著者： 角野佳史¹ 並木幹夫¹

所属機関： ¹金沢大学大学院医学系研究科がん制御学集学的治療学（泌尿器科）

ページ範囲：P.319 - P.324

文献概要

要旨　BCG療法は，再発リスクの高い表在性膀胱癌の再発予防および膀胱上皮内癌に対する治療として確立した方法であるが，最適な投与量・投与方法に関して，いまだ不明な点がある。MVACは転移性膀胱癌の全身療法として，また，浸潤性膀胱癌の周術期補助療法として，長年使用されている有効な治療法である。他の抗癌剤治療の中で，ゲムシタビン・シスプラチン療法（GC）はMVACと同等の効果を示しながら，副作用は軽減されると報告され，欧米ではMVACとともに標準治療とされている。BCGはその使用法に関して，また，MVACは副作用対策や症例選択などについて，それぞれ考慮の余地はあるものの，現在のところ本邦では標準治療といえる。

参考文献

1）Shelley MD, Kynaston H, Court J, et al：A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88：209-216, 2001

2）Han RF and Pan JG：Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?：a meta-analysis of randomized trials. Urology 67：1216-1223, 2006

3）Shelley MD, Wilt TJ, Court J, et al：Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer：a meta-analysis of randomized trials. BJU Int 93：485-490, 2004

4）Böhle A, Jocham D and Bock PR：Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer：a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169：90-95, 2003

5）Sylvester RJ, van der Meijden AP and Lamm DL：Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer：a meta-analysis of the published results of randomized clinical trials. J Urol 168：1964-1970, 2002

6）Sylvester RJ, van der Meijden AP, Oosterlinck W, et al：Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables：a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49：466-477, 2006

7）赤座英之，亀山周二，垣添忠生，他：表在性膀胱癌および膀胱上皮内癌に対するBCG東京172株の膀胱内注入療法の抗腫瘍効果と再発予防効果の検討．日泌尿会誌 83：183-189，1992

8）Böhle A and Bock PR：Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer：formal meta-analysis of comparative studies on tumor progression. Urology 63：682-687, 2004

9）Lamm DL, Blumenstein BA, Crissman JD, et al：Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder：a randomized Southwest Oncology Group Study. J Urol 163：1124-1129, 2000

10）Ojea A, Nogueira JL, Solsona E, et al：A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer：low-dose bacillus Calmette-Guérin（27mg）versus very low-dose bacillus Calmette-Guérin（13.5mg）versus mitomycin C. Eur Urol 52：1398-1406, 2007

11）Yoneyama T, Ohyama C, Imai A, et al：Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection：historical cohort study. Urol 71：1161-1165, 2008

12）Herr HW and Dalbagni G：Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 169：1706-1708, 2003

13）Solsona E, Iborra I, Dumont R, et al：The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164：685-689, 2000

14）Joudi FN, Smith BJ, O'Donnell MA, et al：Final results from a national multicenter phase Ⅱ trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24：344-348, 2006

15）Dalbagni G, Russo P, Bochner B, et al：Phase Ⅱ trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24：2729-2734, 2006

16）Sternberg CN and Vogelzang NJ：Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 46：105-115, 2003

17）Sternberg CN, Yagoda A, Scher HI, et al：Preliminary results of M-VAC（methotrexate, vinblastine, doxorubicin and cisplatin）for transitional cell carcinoma of the urothelium. J Urol 113：403-407, 1985

18）Logothetis CJ, Dexeus FH, Finn L, et al：A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8：1050-1055, 1990

19）Bamias A, Aravantinos G, Deliveliotis C, et al：Docetaxel and cisplatin with granulocyte colony-stimulating factor（G-CSF）versus MVAC with G-CSF in advanced urothelial carcinoma：a multicenter, randomized, phase Ⅲ study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22：220-228, 2004

20）von der Masse H, Hansen SW, Roberts JT, et al：Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer：results of a large, randomized, multinational, multicenter, phase Ⅲ study. J Clin Oncol 17：3068-3077, 2000

21）von der Masse H, Sengelov L, Roberts JT, et al：Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23：4602-4608, 2005

22）Sternberg CN, de Mulder PH, Schornagel JH, et al：Randomized phase Ⅲ trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin（MVAC）chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors：European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19：2638-2646, 2001

23）Sternberg CN, de Mulder PH, Schornagel JH, et al：Seven year update of an EORTC phase Ⅲ trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42：50-54, 2006

24）Petrioli R, Frediani B, Manganelli A, et al：Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients：a randomized phase Ⅱ study. Cancer 77：344-351, 1996

25）Bellmunt J, Ribas A, Eres N, et al：Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80：1966-1972, 1997

26）Albers P, Siener R, Härtlein M, et al：Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma-prognostic factors for response and improvement of quality of life. Onkologie 25：47-52, 2002

27）Sternberg CN, Calabrò F, Pizzocaro G, et al：Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92：2993-2998, 2001

28）Meluch AA, Greco FA, Burris HA 3rd, et al：Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract：a phase Ⅱ trial of the Minnie pearl cancer research network. J Clin Oncol 19：3018-3024, 2001

29）Bajorin DF, Dodd PM, Mazumdar M, et al：Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17：3173-3181, 1999

30）Takata R, Katagiri T, Kanehira M, et al：Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11：2625-2636, 2005

31）Takata R, Katagiri T, Kanehira M, et al：Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 98：113-117, 2007

32）Advanced Bladder Cancer Meta-analysis Collaboration：Neoadjuvant chemotherapy in invasive bladder cancer：a systematic review and meta-analysis. Lancet 361：1922-1934, 2003

33）Winquist E, Kirchner TS, Segal R, et al：Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder：a systematic review and meta-analysis. J Urol 171：561-569, 2004

34）Advanced Bladder Cancer（ABC）Meta-analysis Collaboration：Neoadjuvant chemotherapy in invasive bladder cancer：update of a systematic review and meta-analysis of individual patient data advanced bladder cancer（ABC）meta-analysis collaboration. Eur Urol 48：202-206, 2005